OTO launches AI fertility prediction platform

OTO Fertility  has launched what it claims is a world-first AI fertility prediction platform and wearable to forecast treatment outcomes.

The Toronto-based company says its system pairs a clinical-grade biosensor with an FDA-approved app to track more than 50 markers including heart rate variability (beat-to-beat changes), nervous system regulation and stress response.

The platform, now available across North America, is designed to identify when the body is in what the company calls an optimised “Fertility Zone”.

OTO also claims its Fertility Index is a more accurate indicator of pregnancy success than current standard measures including age, BMI or AMH (anti-Müllerian hormone, a marker used to assess ovarian reserve).

The technology draws on bioscience and space medicine research originally developed by NASA for astronauts and later adapted for elite athletes, according to the company.

Caleb Evans, chief executive and founder of OTO, said: “Until now, there’s been no accurate way to predict fertility outcomes based on what’s actually happening in the body in real time.

“Our solution gives patients a clear understanding of their body’s signals, restores agency, and peace of mind, and provides clinicians with a powerful new layer of insights to guide better outcomes. OTO doesn’t replace existing fertility protocols; it enhances them.

“And for the millions who have done everything right and still struggle to get pregnant, it can help unlock a path forward.”

The company cites figures suggesting one in six women experience infertility globally, while IVF success rates have remained largely static.

OTO Fertility is a division of OTO Coach, a biometric health intelligence company headquartered in Toronto with offices in Vancouver and Helsinki.

The company says clinical programmes are currently underway.